53. Characterisation of TruView™: A new 3-D reusable radiochromic MethylThymol Blue based gel dosimeter for ionising radiations

Introduction Cutting-edge radiotherapy techniques deliver highly conformal treatments with steep dose gradients around the target volume. Thus, the verification of the complex resultant dose distributions presents a real dosimetric challenge requiring accurate and spatially precise dosimeters. Gel dosimetry is a promising technique as it can inform about the whole 3-D dose distribution in one irradiation and without conventional dosimeters issues [1] . This study focuses on the characterisation of the new TruView™ gel dosimeter (Modus Medical Devices Inc.). This dosimeter is based on Fricke-MTB composition [2] but presents a new MethylThymol Blue (MTB) reactive dye and a reusable structure. The dosimetric properties of this gel dosimeter and the influence of different parameters on its response are presented. Methods The key dosimetric aspects (dose response, dependence with energy and dose rate) and the TruView™ dosimeter variability with different parameters (gel temperature, light exposure, time between irradiation and reading, etc.) were studied thanks to spectrophotometric measurements. Finally, by mean of optical CT scanning (Vista™, Modus Medical Devices Inc.), its performances to measure relative depth dose (PDD) and cross profiles have been analysed. Results TruView™ presents linear response with dose up to 20 Gy independent of both photon beam energy and dose rate on the studied ranges. The study of the numerous parameters influencing its dose response enabled to determine the optimal conditions for using this gel. In those conditions, the comparison of TruView™ relative depth dose (PDD) and of cross profiles with ion chamber measurements shows a good dosimetric and spatial precision with 90% of the points passing the 3 mm 3% gamma test for the PDD and 87% for the cross profiles. Seven days after irradiation, ion diffusion inside the gel leads to return to homogeneity allowing a new irradiation to be performed. The TruView™ response presents an excellent reproducibility as 100% of the points pass the gamma test for the comparison between the PDD of the two uses and 94% for the cross profiles. Conclusions This study provides important knowledge regarding the 3-D gel dosimeter TruView™. This dosimeter presents interesting dosimetric properties but remains delicate to use due to the great response sensitivity to numerous parameters. A further study is currently ongoing to benchmark this promising candidate for clinical dose verification.